Transcept Pharmaceuticals

Boston, United States Founded: 1996 • Age: 30 yrs Listed Acquired By Paratek Pharma
Biopharmaceutical company with focus on drugs that target infectious disease, neuromuscular disease, and other difficult to treat conditions

About Transcept Pharmaceuticals

Transcept Pharmaceuticals is a Healthcare company based in Boston (United States) founded in 1996, and was acquired by Paratek Pharma in July 2014. Biopharmaceutical company with focus on drugs that target infectious disease, neuromuscular disease, and other difficult to treat conditions. Transcept Pharmaceuticals has raised $40 million across 2 funding rounds from investors including Hercules Capital, Paratek Pharma and New Leaf Venture Partners. Transcept Pharmaceuticals has completed 1 acquisition, including Novacea. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Bacterial. Its legal entity is Transcept Pharmaceuticals, Inc. Its competitors include Insmed, Affinivax and Lodo Therapeutics; 2 of its 3 listed competitors have raised funding.

Company details

Paratek is focused on the discovery, development, and commercialization of medicines that target infectious disease, neuromuscular disease, and other difficult to treat conditions. Lead product candidate, omadacycline (phase 3), is a new tetracycline-derived, broad-spectrum antibiotic being developed as a first-line monotherapy for serious community-acquired bacterial infections. It is also developing sacrecycline (phase 3) for acne in partnership with Allergan. Other pipeline compounds include 2 molecules in phase 3 for acquired bacterial pneumonia infections and skin structure infections.

  • Headquarters Boston, United States
  • Stage Acquired
  • Sectors
    Healthcare
  • Website transcept.com
  • Social LinkedIn
  • Acquired by Paratek Pharma (Jul 2014)
  • Legal Name Transcept Pharmaceuticals, Inc
Operational Areas
Key Metrics

Funding Insights of Transcept Pharmaceuticals

Transcept Pharmaceuticals has successfully raised a total of $40M across 2 strategic funding rounds. The most recent funding activity was a Series D round of $40 million completed in March 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $40M
  • Total Rounds 2
  • Last Round Series D β€” $40M
  • Investors Count 8

All 2 funding rounds of Transcept Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Mar 2007$40MSeries D––
Jun 2001Series A––
Valuation history

9 investors in total: 9 institutional.

Investors in Transcept Pharmaceuticals

Transcept Pharmaceuticals has secured backing from 9 investors, including venture fund investors. Prominent investors backing the company include Hercules Capital, Paratek Pharma and New Leaf Venture Partners.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Venture capital investments are offered to startups by NEA.
nea.comMenlo Park, United States
Stage-agnostic investments in US life sciences are managed.
2005nlvpartners.comNew York, United States
Venture debt financing is provided to companies in multiple sectors.
2003htgc.comPalo Alto, United States
Early-stage investing in IT and healthcare ventures.
interwest.com
Growth capital investments are made in healthcare and fintech companies.
mepvc.comSan Francisco, United States
Early-stage US tech startups are invested in by Peninsula Ventures.
peninsulaventures.comSan Mateo, United States
Venture capital and private equity firm
vivocapital.comPalo Alto, United States
Biotech funding, drug development support, and investment in life sciences.
sofinnova.com
Therapeutics for antimicrobial resistant infections are developed.
1996paratekpharma.comBoston, United States
Premium access

Investor details for Transcept Pharmaceuticals

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Transcept Pharmaceuticals

Transcept Pharmaceuticals has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Novacea.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Serotonin inhibitor drugs for cancer are developed by Novacea.
novacea.comRichmond, United States2001Sep 2008β€’β€’β€’β€’
Premium access

Complete acquisition details for Transcept Pharmaceuticals

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Transcept Pharmaceuticals

6 dated milestones of Transcept Pharmaceuticals across 18 years, from founding to its latest funding, stage changes and deals.

  1. Founded Transcept Pharmaceuticals is founded.
  2. Funding First funding round.
  3. IPO Lists on the stock exchange (IPO).
  4. Funding Latest funding round, Series D, of $40.0M.
  5. Acquisition Acquires Novacea.
  6. Exit Acquired by Paratek Pharma.

Competitors of Transcept Pharmaceuticals

Transcept Pharmaceuticals has 3 listed competitors in our database, 2 of them funded. They include Insmed, Affinivax and Lodo Therapeutics.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
insmed.com1999Bridgewater, United States912
Developer of small molecule inhibitors for rare lung diseases
affinivax.com2013Cambridge, United States$359.49M132
Technology-based conjugate vaccines against infectious diseases are developed.
lodotherapeutics.com2015New York, United States$19.87M24
Developer novel therapeutics to treat resistant infectious diseases and cancers using AI
Premium access

Detailed competitors of Transcept Pharmaceuticals

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Infectious Diseases

3 companies that operate in the same segment as Transcept Pharmaceuticals (Infectious Diseases) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Developer of molecular diagnostic testing solutions
1996Sunnyvale, California, United StatesUSD 19.1 MUSD 87.11 M4,647
Therapeutics for drug-resistant bacterial infections are developed.
2013Cambridge, Massachusetts, United StatesUSD 114.7 MUSD 59.62 M32
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Transcept Pharmaceuticals

Premium access

Complete news archive for Transcept Pharmaceuticals

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Transcept Pharmaceuticals

Transcept Pharmaceuticals was founded in 1996 and raised its 1st funding round 5 years after it was founded.

Transcept Pharmaceuticals is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.

Transcept Pharmaceuticals is a funded company, having raised a total of $40M across 2 funding rounds to date.

Paratek is focused on the discovery, development, and commercialization of medicines that target infectious disease, neuromuscular disease, and other difficult to treat conditions. Lead product candidate, omadacycline (phase 3), is a new tetracycline-derived, broad-spectrum antibiotic being developed as a first-line monotherapy for serious community-acquired bacterial infections. It is also developing sacrecycline (phase 3) for acne in partnership with Allergan. Other pipeline compounds include 2 molecules in phase 3 for acquired bacterial pneumonia infections and skin structure infections.

Transcept Pharmaceuticals's top competitors include Insmed, Affinivax and Lodo Therapeutics.

Transcept Pharmaceuticals has made 1 acquisition, including Novacea.

Transcept Pharmaceuticals has 9 investors. Key investors include Hercules Capital, Paratek Pharma, New Leaf Venture Partners, NEA, and InterWest.

Transcept Pharmaceuticals operates through Transcept Pharmaceuticals, Inc.

Yes. Transcept Pharmaceuticals was acquired by Paratek Pharma in July 2014.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available